Machaca-Luque Laura Yesenia, Candia-Puma Mayron Antonio, Roque-Pumahuanca Brychs Milagros, Barazorda-Ccahuana Haruna Luz, Goyzueta-Mamani Luis Daniel, Sobreira Galdino Alexsandro, Machado-de-Ávila Ricardo Andrez, Cordeiro Giunchetti Rodolfo Cordeiro, Ferraz Coelho Eduardo Antonio, Chavez-Fumagalli Miguel Angel
Facultad de Ciencias Farmacéuticas, Bioquímicas y Biotecnológicas, Universidad Católica de Santa María, Arequipa, 04000, Peru.
Computational Biology and Chemistry Research Group, Vicerrectorado de Investigación, Universidad Católica de Santa María, Pedro Vilcapaza, Arequipa, 04000, Peru.
F1000Res. 2025 May 16;13:885. doi: 10.12688/f1000research.150723.1. eCollection 2024.
Chagas disease (CD) is a neglected tropical disease endemic to Latin America, has emerged as a global health concern due to the migration of infected individuals. With its epidemiological complexity, by difficulty to obtain appropriate diagnoses and poor treatment, the search for novel therapeutic options remains.
In this context, we conducted a systematic review and meta-analysis of preclinical studies employing animal models to verify the progress in CD treatment. We searched the PubMed database for CD treatment studies published between 1990 and 2023, adhering to the PRISMA guidelines.
Twelve papers met the inclusion criteria. The findings indicate that the fifteen treatment alternatives examined, mainly between 2010 and 2014, demonstrated efficacy in experimental CD models, evidenced by significant parasitemia reduction. Bis-triazole DO870 and VNI were effective in the acute and chronic phases, respectively. However, of these emerging therapies, only posaconazole and fexinidazole have progressed to clinical trials, yielding unsatisfactory outcomes as CD monotherapies.
This meta-analysis highlights the existence of promising new drug candidates for CD treatment, but most remain in the preclinical stages. Those that reached clinical trials did not demonstrate optimal results, underscoring the ongoing challenges in CD therapy. Collaborative efforts among the academic community, pharmaceutical industries, funding agencies, and government agencies are urgently needed to accelerate the development of more effective medications against CD.
INPLASY202430101 (25/03/2024).
恰加斯病（CD）是拉丁美洲特有的一种被忽视的热带疾病，由于受感染个体的迁移，已成为全球卫生关注的问题。鉴于其流行病学的复杂性、难以获得适当诊断以及治疗效果不佳，仍需寻找新的治疗选择。
在此背景下，我们对采用动物模型的临床前研究进行了系统综述和荟萃分析，以验证CD治疗的进展。我们按照PRISMA指南，在PubMed数据库中搜索了1990年至2023年发表的CD治疗研究。
12篇论文符合纳入标准。研究结果表明，所研究的15种治疗方案，主要在2010年至2014年期间，在实验性CD模型中显示出疗效，显著降低寄生虫血症证明了这一点。双三唑DO870和VNI分别在急性期和慢性期有效。然而，在这些新兴疗法中，只有泊沙康唑和非昔硝唑进入了临床试验，但作为CD单一疗法，结果并不理想。
这项荟萃分析突出了存在有前景的CD治疗新药候选物，但大多数仍处于临床前阶段。那些进入临床试验的药物并未显示出最佳效果，这凸显了CD治疗中持续存在的挑战。迫切需要学术界、制药行业、资助机构和政府机构之间的合作努力，以加速开发更有效的抗CD药物。
INPLASY注册：INPLASY202430101（2024年3月25日）。
